secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001437749-25-016838
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia Q1 2025 net loss $2.7M; CardiAMP HF two-year data shows survival benefit; Helix FDA submission planned
--------------------------------------------------------------------------------

- Two-year results from Phase 3 CardiAMP HF trial (presented Mar 30) showed increased survival, fewer CV events, improved QoL; significant in NTproBNP-elevated subset (p=0.02).
- CardiAMP HF II confirmatory trial underway with three active sites; primary endpoint based on hierarchical analysis.
- Refractory angina roll-in cohort showed 107 sec increase in exercise tolerance and 82% reduction in angina episodes at 6 months.
- R&D expenses $1.5M, SG&A $1.2M; net loss $2.7M vs $2.3M YoY; cash used in ops $1.6M.
- Plans to submit CardiAMP Cell Therapy for Japan PMDA consultation and Helix delivery system for FDA approval this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925016838/0001437749-25-016838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925016838/bcda20250513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer